Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected...

Por Ofotokun, Ighovwerha, Chuck, Susan K, Schmotzer, Brian, O'Neil, Kelly L
Publicado em 2009

Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared w...

Por Schrader, Shannon, Chuck, Susan K, Rahn, Laurie W, Parekh, Paras, Emrich, Katherine G
Publicado em 2008

Lopinavir/Ritonavir Pharmacokinetic Profile: Impact of Sex and Other Covariates Following a Change From Twice-Daily to Once-Daily Therapy

Por Ofotokun, Ighovwerha, Chuck, Susan K., Binongo, Jose N., Palau, Mauricio, Lennox, Jeffrey L., Acosta, Edward P.
Publicado em 2007

Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1–Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 Pooled ECHO/THRI...

Por Behrens, Georg, Rijnders, Bart, Nelson, Mark, Orkin, Chloe, Cohen, Calvin, Mills, Anthony, Elion, Richard A., Vanveggel, Simon, Stevens, Marita, Rimsky, Laurence, Thorpe, David, Bosse, Matthew, White, Kirsten, Zhong, Lijie, DeMorin, Jennifer, Chuck, Susan K.
Publicado em 2014